Open Orphan wins another contract renewal with pharma major
Pharmaceutical services contract research organisation Open Orphan announced a further contract renewal with a major top-three global pharmaceutical client on Wednesday, extending its consultancy services to the end of December.
The AIM-traded firm said the renewal followed on from its announcement on 22 December over the same client.
It said its Venn team in the Breda office would provide chemistry, manufacturing and control consultancy services to the client for one of its vaccine development programmes, and followed the recently-announced contract renewal for work on two of the client's vaccine development programmes.
“We are delighted to enter 2021 with another contract signed by the Venn team in Breda with this top-three global pharmaceutical client,” said executive chairman Cathal Friel.
“Venn have been providing CMC support to this top tier company since 2012 and are pleased to be continuing to work with this client in their vaccine development programme.
“This contract demonstrates the depth of vaccine development knowledge across the company and, in addition to being the world leader in vaccine and antiviral testing using human challenge clinical trials, reinforces our position as the go-to clinical research organisation for many other services required by both large pharma and vaccine developers at all stages of development.”
At 1533 GMT, shares in Open Orphan were down 2.45% at 26.83p.